EGFR and non-small cell lung carcinoma: Thus, we conducted this network meta-analysis [12], which is widely used in the absence of data from head-to-head trials, integrating the most recent results from RCTs and synthesizing indirect evidence to investigate the efficacy and safety of combination therapies of EGFR-TKI as a first-line treatment in patients with advanced EGFR mutated NSCLC, drawing more robust conclusions for determining the best clinical choice.